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Abstract
Background: Government social assistance payments seek to alleviate poverty and address survival needs, but their
monthly disbursement may cue increases in illicit drug use. This cue may be magnified when assistance is
disbursed simultaneously across the population. Synchronized payments have been linked to escalations in drug
use and unintended but severe drug-related harms, including overdose, as well as spikes in demand for health,
social, financial and police services.
Methods/design: The TASA study examines whether changing payment timing and frequency can mitigate
drug-related harm associated with synchronized social assistance disbursement. The study is a parallel arm
multi-group randomized controlled trial in which 273 participants are randomly allocated for six assistance
cycles to a control or one of two intervention arms on a 1:1:1 basis. Intervention arm participants receive
their payments: (1) monthly; or (2) semi-monthly, in each case on days that are not during the week when
cheques are normally issued. The study partners with a community-based credit union that has developed
a system to vary social assistance payment timing. The primary outcome is a 40 % increase in drug use
during the 3 days beginning with cheque issue day compared to other days of the month. Bi-weekly
follow-up interviews collect participant information on this and secondary outcomes of interest, including
drug-related harm (e.g. non-fatal overdose), exposure to violence and health service utilization. Self-reported
data will be supplemented with participant information from health, financial, police and government
administrative databases. A longitudinal, nested, qualitative parallel process evaluation explores participant
experiences, and a cost-effectiveness evaluation of different disbursement scenarios will be undertaken.
Outcomes will be compared between control and intervention arms to identify the impacts of alternative
disbursement schedules on drug-related harm resulting from synchronized income assistance.
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Discussion: This structural RCT benefits from strong community partnerships, highly detailed outcome
measurement, robust methods of randomization and data triangulation with third party administrative
databases. The study will provide evidence regarding the potential importance of social assistance program
design as a lever to support population health outcomes and service provision for populations with a high
prevalence of substance use.
Trial registration: NCT02457949 Registered 13 May 2015.
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Background
Social assistance, including disability support, income
assistance or other state-provided cash transfer
benefits, is commonly distributed on a monthly basis
[1, 2], and can provide important protection against
the harms associated with extreme poverty [2].
Recipients of social assistance commonly increase
general consumption following benefit receipt [3].
For people who use illicit drugs (PWUD), receipt of
such benefits may also serve as a cue for intensified
drug use [4] that is magnified when receipt is
synchronized across the population [5–7]. Previous
observational research has linked monthly social as-
sistance payments to unintentional, yet cyclical and
severe increases in drug-related harms [7–9], as well
as increased demand for health, social, financial and
police services [6–8, 10–13]. While there have been
repeated calls for interventions to mitigate drug-
related harms associated with synchronized social as-
sistance [7, 8, 12], research to date has been limited
to observational studies and a single natural experi-
ment. We have therefore designed and undertaken a
controlled, experimental study that examines whether
changing the timing and frequency of social assistance
cash transfers can reduce drug-related harm linked to
the synchronization of such payments.
Socioeconomically marginalized PWUD commonly rely
on social assistance as a critical source of income [14, 15].
However, the temporal synchronization of such payments
has significant consequences for PWUD, their social
contacts and service providers. Specifically, previous re-
search has linked payment timing to high intensity drug
use [6, 10, 16], higher risk drug use [5], increased sobering
or detoxification unit admissions [7, 17], drug-related
emergency department use and hospitalization [11, 13, 16,
18, 19], fatal and non-fatal overdose [5, 7, 12, 20, 21]
hospital discharges against medical advice [9, 22], public
disorder [7, 11], addiction and HIV treatment interruption
[9, 22, 23], mental health apprehensions [24] and barriers
to health service access [6]. Additionally, such increases
impact demands on health, social, financial and police
service provision. For example, providers have noted sig-
nificant increases in patient volumes for harm reduction
services such as supervised injecting sites [6], emergency
department and psychiatric emergency services, police
service calls and increases in cash outlays from financial
service providers located in inner-city neighbourhoods (M.
Corral, J. Chu, J. Fahey, personal correspondence). Chal-
lenges related to service provision are taxing for providers,
interfere with their ability to provide quality and timely
services and may result in individuals leaving service sites
before accessing critical supports [6].
Initial documentation of drug use coinciding with
cheque issue pointed to a “cheque effect”, where drug
use was attributed to the provision of disability
assistance [10]. A recent review examined whether dis-
ability payments are the cause of increased illicit drug
use overall or whether they simply alter the timing of
drug use [8]. Findings found no difference in overall
rates of drug use between those receiving or not receiv-
ing disability benefits, but that payments and spikes in
drug use intensity were linked. Delayed payments have
produced corresponding delays in rates of drug-related
hospitalization [8]. Studies provide a strong signal, first,
that payments do not alter whether people use drugs,
and second, that payment timing may be an important
lever through which to influence payment-related in-
creases in drug use and consequent harm. In addition, a
strong rationale for leveraging pay frequency in order to
smooth consumption patterns exists [25], although this
has not been explored among PWUD. Smaller, more
regular payments may further decrease or potentially
disperse drug use and related harm. Despite indications
that changing the timing and frequency of payments
could significantly benefit PWUD, their communities
and service providers, there is no evidence from con-
trolled experiments identifying the impacts of such a
strategy. This is a critical gap given the health, social and
economic costs of drug-related harm associated with
cheque issue and potentially important implications for
social assistance policy.
Drug-related concerns coinciding with cheque issue
may be particularly acute in inner-city neighbourhoods
with higher prevalence of illicit drug use and
concentrations of social assistance recipients [26]. The
Downtown Eastside (DTES) neighbourhood in Vancouver,
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Canada is one such area, commonly characterized by: high
rates of poverty; an open drug market; high prevalence of
illicit drug use, mental health disorders, and HIV
infection; and a large proportion of residents receiving
government assistance [27]. Cheque issue days, generally
on the last Wednesday of each month, are referred to
locally as “Cheque Day” or “Welfare Wednesday”. The
widespread and severe harms produced by synchronized
social assistance are widely acknowledged among commu-
nity members and service providers and have been docu-
mented by over 20 years of ongoing observational research
[7, 24, 28]. The identification of public health- and
community safety-promoting approaches to the dis-
bursement of social assistance is therefore an urgent
public health and community safety priority in
Vancouver as elsewhere, with significant implications
for policy and service provision.
We have therefore designed and initiated a prospective
randomized controlled trial (RCT), the impact of Alterna-
tive Social Assistance disbursement on drug-related harm
(TASA) study, to examine whether changing the timing
and frequency of social assistance cash transfers can
reduce drug-related harm linked to the synchronization of
such payments. The TASA study is a demonstration pro-
ject of the British Columbia node of the Canadian
Research Initiative in Substance Misuse (CRISM). The
study changes the temporal conditions of social assistance
receipt to determine which disbursement arrangement
most effectively mitigates escalations in drug-related
health, social and economic harm associated with social
assistance cheque issue days. Contrasted with behavioural
interventions that seek to directly alter individual behav-
iour, the study is a structural intervention that alters the
context (i.e., socio-economic environment) in which
health risks are produced [29]. TASA focuses on both the
timing and frequency of income assistance payments by
comparing two distinct interventions. The first involves
the disbursement of income assistance payments once a
month, as is currently the case. However, payments are
made on a day that does not fall during cheque issue
week, and participants are randomized to different days,
rather than all intervention participants receiving payment
on the same non-government cheque issue day. This
allows us to determine whether staggering payments
separates individual cues for drug use following individual
payment from the social cues for increased drug use that
accompany synchronized payments from all participants
being paid on the same day. The second intervention
involves twice-monthly payments, similarly on days that
do not fall during cheque issue week and not on the same
day for all participants. In addition to differentiating
between individual and social cues for drug use, this strat-
egy tests whether splitting income assistance payments
can reduce drug use by smoothing consumption patterns.
Both interventions are administered through Pigeon Park
Savings, a branch of Vancouver City Savings Credit Union
in the DTES specifically designed to support residents
who face barriers to accessing services at other financial
institutions.
There are potentially important differences between
the two interventions that may affect their relative effi-
cacy. For example, staggering social assistance payments
could displace consumption for individuals away from
government cheque issue, but may not reduce overall
consumption. At scale, this may improve experiences of
service providers who would not have to manage cyclical
escalations in service demand, but may provide little
benefit to individual PWUD other than improved service
access. Staggering and splitting income assistance pay-
ments may support smoothing consumption patterns, but
may potentially result in multiple periods of escalated
drug use signaled by more than one monthly payment.
The testing of two different payment schedules enables us
to examine which approach, if either, more effectively
decreases spikes in drug use and drug-related harm coin-
ciding with synchronized social assistance disbursement.
Objectives
The main objective of TASA Cheque issue study is to as-
sess the effectiveness of structural changes in the timing
and frequency of social assistance payments in reducing
drug use and drug-related harm in the days surrounding
social assistance cheque issue in a population of socio-
economically marginalized people who use illicit drugs.
The interventions will be compared with each other and
with a no-intervention control group.
Methods/design
Study design
The TASA Cheque Issue study is an exploratory, parallel-
group, unblinded, randomized controlled trial involving
the allocation of 273 participants to either no intervention
(control group), where participants continue to receive
their provincial social assistance on government cheque
issue day, or to one of two intervention groups: (1)
monthly social assistance payment on a day that does not
fall during cheque issue week (staggered group), or (2)
semi-monthly on days that do not fall during cheque issue
week (split and staggered group). Participants will be
under active observation for six income assistance cycles,
or approximately six months. The primary outcome of
interest is increased frequency, street value, or number
substances other than cannabis used in the 3 days starting
with government cheque issue day as assessed by the stan-
dardized Timeline Followback instrument [30, 31]. The
pre-specified secondary outcomes are: overall monthly
drug use; increased drug use on individual cheque issue
days; drug-related risk, including non-fatal overdose;
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barriers to service access; exposure to violence; interac-
tions with police; emergency department (ED), emergency
department mental health (EDMH) and substance use
hospitalization (SUH) admissions; leaving hospital against
medical advice (AMA); health care interruption or discon-
tinuation; and changes in spending patterns as repre-
sented by the amount of time with little or no money
present in the participant’s bank account. The TASA study
incorporates a longitudinal nested qualitative parallel
process evaluation [32] and a cost-effectiveness analysis
comparing the costs of different social assistance disburse-
ment arrangements in terms of police, judicial, correc-
tions, crime victimization, productivity, and health care
costs. The design of the trial and flow of participants are
shown in Fig. 1 (Protocol version 6.6, 14 December 2015).
Eligibility and recruitment
Individuals are eligible for the study if they are 19 years
of age or older, report active and regular use of drugs
other than cannabis, currently receive provincial social
assistance payments on a monthly basis, report intensi-
fied drug use at the time of cheque issue days in the six
months prior to recruitment, are eligible and willing to
be a client of Pigeon Park Savings, and are not currently
administered (where a third party manages their social
assistance, often disbursing funds in smaller amounts).
Cannabis is excluded from the TASA outcomes of inter-
est and study eligibility criteria due to its lower risk pro-
file [33] and to be consistent with standard research
practice in the study context [34, 35]. Individuals are
ineligible if they have imminent plans to relocate outside
the greater Vancouver area or discontinue their social
assistance receipt, have outstanding criminal justice sys-
tem involvement that could result in incarceration, or
have been barred from membership at Pigeon Park Sav-
ings. Recruitment follows a multi-pronged approach.
Three ongoing prospective cohort studies of people who
use illicit drugs in Vancouver, Canada [36] have recently
added the following question to their research instru-
ments: “Did any of the following things ever happen to
you in the days around cheque day?” The question is
followed by a set of response options representing differ-
ent types of drug-related harm, and is used to identify
prospective participants for referral to the TASA study.
Additional recruitment efforts utilize community-based
methods, including advertisements at PWUD advocacy
organizations, street-based outreach and word of mouth
through the study team’s established contacts. Local
health, social and financial and service providers have
additionally agreed to refer clients who meet the
Fig. 1 Flow of participants through the TASA trial
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eligibility criteria and to post advertisements for the
study in their offices. The study also recruits participants
through the network of addiction physicians practicing
in the local health authority. Recruitment takes place on
a continuous rolling basis over an 18-month period, with
the final participant completing the intervention 2 years
after the start of recruitment.
Screening, consent and baseline assessment
Individuals expressing interest in the study are adminis-
tered a brief screening questionnaire by study staff to deter-
mine whether they fulfill eligibility criteria. This includes
confirmation that participants are willing and able to
adhere to study procedures. Participants are required to
provide proof of non-administered provincial social assist-
ance receipt in the form of an official statement of benefits,
recent bank statement, or cheque stub from a recent social
assistance cash transfer. Additionally, government-issued
identification is needed as verification of identity and to
open a bank account at Pigeon Park Savings. Study proce-
dures and requirements are then explained to potential
participants to confirm participant interest and suitability.
During the consent process, research staff explain
study procedures, potential risks and benefits of partici-
pation, planned data linkages to third party administra-
tive data sets and other consent information outlined in
the informed consent form. As is common for RCTs,
after signing the consent form participants undergo a
short oral “consent quiz” to ensure full comprehension
of key points such as voluntary consent, randomization,
confidentiality, study design and procedures, and with-
drawal processes. Individuals receive additional informa-
tion from study staff on any areas of misunderstanding
identified by the quiz.
Following informed consent and prior to randomization,
participants complete an interviewer-administered base-
line assessment. This assessment includes the collection
of demographic information and completion of question-
naire items to assess drug use, income generation and
material security, drug-related activities and exposures,
criminal activity, police contact, exposure to violence,
drug debt, addiction treatment enrolment, health and
social service use, cheque day activities and health related
quality of life (see Measures section and Table 1). Baseline
measures are collected for past 6-month as well as past 2-
week time frames to ensure sufficient background infor-
mation as well as data consistent with the 2-week time
frame of follow-up observations.
Randomization, allocation concealment and blinding
Once participants complete the consent process and base-
line procedures, they are randomized to one of the con-
trol, staggered, or staggered and split study arms by the
study coordinator using a 1:1:1 allocation ratio. The study
employs a stratified block randomization procedure [37]
where randomly sized blocks comprised of equal numbers
of recipients of the three main types of provincial social
assistance (standard employable income assistance sup-
port, persons facing persistent multiple barriers, persons
with disability) are allocated to each of the three study
arms. Block sizes are random multiples of three to ensure
the proportional allocation of recipients of each category
of social assistance to each study arm. The randomization
algorithm was developed by the study statistician in SAS
software v9.4 (SAS, Cary, North Carolina, USA) and was
embedded in the participant tracking system to allow for
easy, on-site randomization following the completion of
all study enrollment and baseline procedures and
allocation concealment until randomization.
Notably, it is not possible to conceal study arm alloca-
tion from participants, given the potentially significant
changes to their social assistance arrangements from the
study intervention. It is also not possible to have an
assessor-blinded trial, as study assessors track participant
activities in relation to government as well as individual
cheque issue days, thereby revealing study arm alloca-




Participants randomized to this study arm receive no
intervention. They continue to receive monthly social
assistance payments according to the British Columbia
Ministry of Social Development and Social Innovation
disbursement schedule.
Staggered social assistance disbursement (staggered
Participants in the ‘staggered’ intervention study arm
have access to their social assistance payments on a
monthly basis on a day that does not fall during govern-
ment cheque issue week and that is not the same as all
other participants in the staggered arm. Due to the vari-
ation in government cheque issue day timing, which
ranges from the 16th to the 29th of the month, individual
cheque issue is allocated relative to government cheque
issue day (e.g., Tuesday the week after cheque issue).
Participants undergo a transition period during which
they receive their social assistance up to 7 days later
each month until they reach their study cheque issue
date. This transition period ensures that participants do
not have a time period between payments any longer
than the longest period between payments on the
government schedule, which is 35 days. To facilitate
timely transitions to the new disbursement schedule
within the timeframe of the intervention, possibilities for
individual cheque issue is are limited to business days
during the first and second week following government
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Table 1 Measures used in the TASA Trial
Follow-up (FU) period Post-follow-up
Measure(s) Screen Baseline FU 1-13 Intervention withdrawal Study exit 60-day visit Data linkage
Primary Outcome Measure
Daily Drug Use (TLFB) ✓ ✓ ✓
Demographic Measures





Residency / housing status ✓ ✓ ✓ ✓
Drug Related Activity/Exposures
Drug use (past six months) ✓
Expenditure on drugs ✓ ✓ ✓
Binge drug use ✓ ✓ ✓
Distributive and acquisitive syringe sharing ✓ ✓ ✓
Crack pipe and drug equipment sharing ✓ ✓ ✓
Assistance injecting ✓ ✓ ✓
Public drug use ✓ ✓ ✓
Non-fatal overdose ✓ ✓ ✓
Addiction treatment and harm reduction
Addiction treatment (type, timing) ✓ ✓ ✓
Treatment interruptions/missed visits ✓ ✓ ✓
Supervised injection facility use ✓ ✓ ✓
Police contact and illegal activity
Police contact (frequency, type) ✓ ✓ ✓
Criminal activity ✓ ✓ ✓
Exposure to Violence
Exposure to violence (frequency, type) ✓ ✓ ✓
Type of perpetrator ✓ ✓ ✓
Police/medical involvement ✓ ✓ ✓
Timing ✓ ✓ ✓
Health and Social Service Use
Service accessed ✓ ✓ ✓
Barriers to service access (type, timing) ✓ ✓ ✓
Missed appointments ✓ ✓ ✓
Leaving hospital against medical advice ✓ ✓ ✓
Income and Financial Information
Social assistance income ✓ ✓
Additional Income Sources ✓ ✓ ✓
Material security ✓ ✓ ✓
Daily income generation activity ✓ ✓ ✓
Banking practices ✓
Drug Debt ✓ ✓ ✓
Government cheque day activities ✓ ✓ ✓
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cheque issue day. This allows for 10 possible payment
schedules for participants in the staggered arm. The
exact date of disbursement is determined at random
through a second randomization procedure. Study staff
provide each participant with a detailed payment sched-
ule to assist participant recall.
Staggered and split and social assistance disbursement
(staggered and split)
Participants in the ‘staggered and split’ intervention
study arm have their social assistance payments released
twice a month on days that do not fall during the week
of government cheque issue. The days of income assist-
ance receipt are spaced 2 weeks apart and determined at
random. As with the staggered intervention arm, indi-
vidual cheque issue days are established in relation to
government cheque issue day and participants transition
to their new schedule incrementally. The first individual
cheque issue day falls in the week following government
cheque issue, with the second occurring on the corre-
sponding day of the week 2 weeks later. This could be,
for example, Tuesday of the week following government
cheque issue day and Tuesday 2 weeks after that day.
This allows for five randomization possibilities for the stag-
gered and split intervention study arm. Participants are
again provided with a schedule of their individual cheque
issue days for the duration of their study participation.
The change in social assistance payment schedules for
both intervention arms is managed through Pigeon Park
Savings, which has developed a system, in conjunction with
standard social assistance direct deposit services from the
British Columbia Ministry of Social Development and
Social Innovation, that varies when individuals have access
to their social assistance payments. Social assistance pay-
ments are directly deposited into the participant’s account,
and the system “locks” their payment so that these funds
cannot be withdrawn. Money is “unlocked” according to
the participant’s disbursement schedule that determines
both the timing and frequency at which payments are
released. Intervention arm participants can develop person-
alized arrangements that ensure access to essential funds at
specific times to prevent housing instability or payment
default. A study liaison at Pigeon Park Savings manages
account creation, direct deposit requests to the Ministry
and the implementation of holds and releases of funds. Ac-
counts include unlimited withdrawals and a bank card with
no-fee withdrawals at credit union automated teller
machines. Pigeon Park Savings banking fees are charged at
a rate of $5/month, and individuals are not required to pay
this fee while they are enrolled in the study.
Follow-up assessments
Once individuals enrol (control arm) or receive their
first payment on their individual schedule (staggered and
Table 1 Measures used in the TASA Trial (Continued)
Individual cheque day activities ✓ ✓
Health-related quality of life
Euro-QoL (EQ-5D) ✓ ✓ ✓
Study-related measures
Motivation to participate ✓
Treatment preferences ✓ ✓
Client satisfaction questionnaire (CSQ-4) ✓ ✓
Reasons for intervention withdrawal ✓
Duration of intervention ✓
Participant experiences ✓
External Data Sources
Hospital, ED, EDMH, SUH records
Community and primary service records ✓
Emergency health services records ✓
Supervised injection facility records ✓
Prescribed medications ✓
Banking records (VanCity) ✓
Ministry of Social Development & Social ✓
Innovation assistance receipt records ✓
Police contact records ✓
Abbreviations: FU follow-up, TLFB timeline follow back, ED Emergency Department, EDMH Emergency Department Mental Health, SUH substance
use hospitalization
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staggered and split) arms, follow-up visits occur every
2 weeks for the 26-week period of active study participa-
tion, for a total of one baseline and 13 regular follow-up
interviews. Frequent follow-up visits mitigate recall-
related threats to data reliability for key measures [38].
During study follow-up visits, a trained interviewer
administers the follow-up questionnaire, which includes
past 2 week assessments of all study measures. Participant
safety, including the monitoring of adverse events or
serious adverse events related and unrelated to study par-
ticipation is also assessed at every follow-up. Follow-up
visits take 20–30 min. Due to the intent-to-treat nature of
the study, participants can withdraw from the intervention
but are encouraged to continue to complete regular
follow-up visits.
Qualitative parallel process evaluation
The TASA study also includes a qualitative parallel
process evaluation concurrent to the quantitative
survey-based evaluation of the study interventions.
This evaluation is comprised of a longitudinal, nested
study involving a sub-population of TASA study par-
ticipants who complete three qualitative interviews
each, the first at baseline, the second at their study
mid-point and the third at study completion or with-
drawal. Following randomization to the study inter-
ventions, approximately 45–50 participants are
selected to be participants in a qualitative parallel
process evaluation. Quota sampling ensures hetero-
geneity across categories of social assistance, drug use
practices and study arms, with a weighted distribution
focusing on the experiences of individuals allocated to
the intervention arms (8–10 participants recruited
from control versus 15–20 from each intervention
arm). Following a separate informed consent process
specific to qualitative participants, audio-recorded in-
terviews are conducted by trained qualitative inter-
viewers in private settings at the study site. Data
collection follows principles of data saturation in
which the study team continues to recruit participants
until no new themes emerge in relation to key topics
from interviews among individuals in each of the
study arms [39, 40]. Interviews employ topic guides
informed by previous studies conducted by the inves-
tigative team [5, 6, 41] and a comprehensive review
of the relevant literature. Baseline interviews explore
prior experiences of social assistance receipt, income
and material hardship, substance use patterns, and fi-
nancial management. Midpoint interviews focus on
transitions to new payment schedules as well as
changes in material circumstances, financial manage-
ment, drug use patterns and expenditure on drugs.
Exit interviews explore study experiences of social
assistance receipt and broader changes to life circum-
stances (e.g. income, housing), drug use and drug-
related activity, and reasons for study or intervention
withdrawal, where applicable. Initial interviews inform
subsequent interviews among the same participants,
building on previous responses and benefits or chal-
lenges previously identified by participants.
Study completion and post-evaluation questionnaires
At the final regular follow-up study visit, participants are
administered a study completion questionnaire that
assesses, in addition to regular follow-up measures, their
participation experiences and opinions about the inter-
vention. Sixty days post study completion, a follow-up
interview is administered to assess the safety of partici-
pants and any significant changes following the comple-
tion of the study protocol. Participants in all study arms
are able to access the study intervention of their choice
following the completion of their participation should
they wish to do so. Screening, baseline, follow-up, quali-
tative and post-evaluation study visits take place at a
purpose-built field research office located in the DTES
and operated by the British Columbia Centre for Excel-
lence in HIV/AIDS. If needed, follow-up visits can take
place at the participant’s residence, over the phone, or
other space considered safe by the participant.
Participant honoraria
Consistent with standard practice in research involving
PWUD [34, 42], participants are compensated for their
time and interview-related expenses with honoraria in the
following Canadian dollar (CAD) amounts: $30 for base-
line/randomization visit; $10 per follow-up interview, with
follow-up interview incentive bonuses following the first
post-baseline follow-up ($10), the completion of five
follow-up interviews ($15), the completion of nine follow-
up interviews ($20) and the completion of the final follow-
up interview ($25). The post study follow-up interview
honorarium is $15. The honorarium for each qualitative
interview is $30 per interview. Participants will therefore
receive a maximum of $245 for participation in the quanti-
tative portion of the study and $335 for participation in
both the qualitative and quantitative study components.
Measures
Table 1 outlines the measures taken at screening, baseline,
follow-up, withdrawal and study exit interviews and
through post-study data linkages. For all primary and sec-
ondary outcomes of interest described below, we collect
data on indicators on government cheque issue days by
tracking activity and exposures on a daily basis or through
specific questionnaire items and response options. Where
government cheque issue and individual cheque issue
timing are not the same (i.e., for intervention participants),
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we additionally ask specific questions about individual
cheque issue day activities and exposures. By collecting in-
formation about the occurrence of key outcomes of inter-
est on non-cheque issue days as well as those coinciding
with government and individual payments, we are better
able to distinguish between individual cues for increased
drug use coinciding with individual payments and social
cues prompted by synchronized payment across the popu-
lation on government cheque issue day.
Socio-demographic information and housing status
Socio-demographic information, collected at baseline,
includes standardized measures of age, gender, ethnicity,
relationship status and highest level of educational
attainment. Self-reported measures of residency and
housing status include neighbourhood of residence, type
of residence (e.g. house, apartment, single room occu-
pancy hotel [43], no fixed address), and housing stability,
measured by the number of residences occupied in the
last six months (baseline) or past 2 weeks (baseline and
follow-up).
Drug use (timeline follow back; primary outcome measure)
The TASA study’s primary outcome is increased in-
tensity of drug use on government cheque issue day
(i.e. a binary outcome). Participant drug use is consid-
ered to have intensified if, in the 3 days starting with
government cheque issue day, a participant increases
by 40 %: (1) the daily frequency of non-cannabis drug
use; (2) the street value of drugs consumed; or (3)
the number of non-cannabis substances used, includ-
ing alcohol and illicit prescription opioids, all com-
pared to the average frequency, value of drugs used
or number of substances used on all other days of
the calendar month. For example, if an individual
uses crack cocaine once daily on non-cheque issue
days and does not use methamphetamine, but in-
creases uses crack cocaine 3 times per day and meth-
amphetamine once per day on the 3 days beginning
with cheque issue day, they will have intensified their
use according to the first and second criteria. These
cut points were selected based on prior empirical
studies [8] and our intention to capture changes
among high-intensity users that could be overlooked
if more blunt measures common to RCTs among
PWUD, such as daily drug use [44], are used. Staff
gather data measuring the primary outcome using the
Timeline Follow Back (TLFB) instrument, a reliable,
validated, calendric instrument that collects daily in-
formation on drug use patterns, including drugs used
and frequency of use [30, 31]. We additionally collect
participant estimates of the street value of drugs used
as a proxy for quantity or dosage of drug consumed,
which may not be captured by drug use frequency
measures [45, 46]. We also use daily TLFB drug use
data to assess our key secondary outcome of intensi-
fied drug use on individual cheque issue days, identi-
fied using the same frequency, street value or number
of drugs criteria as intensified drug use on
government cheque issue day.
Drug-related activities and exposures
A range of activities and exposures has been associated
with increased risk of drug-related morbidity and mortality
as well as social and community harms [47–51]. To
support analyses of secondary outcomes of interest, past six
month (baseline) and past 2 week (baseline and follow-up)
self-reported measures for drug use-related activities and
exposures include: changes in drug use patterns (e.g., binge
or greater than average drug use); distributive and acquisi-
tive syringe, crack pipe or drug equipment sharing; receiv-
ing an assisted injection; public injection and non-injection
drug use; and non-fatal overdose. Questionnaire items have
previously been verified for use in the current study context
through longstanding cohort studies involving PWUD [52].
Addiction treatment enrolment and harm reduction service
use
Past six month (baseline) and past 2 week (baseline and
follow-up) data on addiction treatment enrolment are
collected for secondary analyses about addiction treat-
ment interruption. Questions include the type of addic-
tion treatment, interruptions to ongoing opioid assisted
or other treatments, missed visits, the reasons for addic-
tion treatment interruption (if any), and the impacts of
treatment interruptions or missed visits (e.g., relapse,
withdrawal). We additionally ask participants about past
six month (baseline) and past 2 weeks (baseline and
follow-up) use of Insite, a local supervised injection facil-
ity (SIF), given the association between exposure to the
SIF and significant improvements in in morbidity, mor-
tality, uptake of addiction treatment uptake and mea-
sures of public order [53].
Police contact and illegal activity
While drug market enforcement has been shown to have
adverse public health and social impacts [54], studies
have also identified police as critical supports for public
health and community safety initiatives [55]. We collect
data on all police interactions, and the measures used in
the current study facilitate distinctions between different
types of police contact (e.g., service referral, arrest), as
well as participant perceptions of the reason for contact.
In support of economic analyses, we also collect data
about engagement in illegal activity to assess any changes
in the costs of criminality and victimization as a result of
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the intervention, with past six month (baseline) and past
2 week (baseline and follow-up) recall periods.
Exposure to violence
Consistent with previous analyses documenting the rela-
tionship between socio-economic marginalization and
exposure to violence [56], the TASA study also seeks to
document whether varying social assistance payments
impacts participants’ exposure to violence. The study in-
strument includes measures to identify the frequency,
timing and type of violence victims were exposed to, the
type of perpetrator (e.g. stranger, intimate partner) and
whether the participant sought police or medical atten-
tion. The study solicits analogous information regarding
the perpetration of violence.
Health service utilization
Several key secondary outcomes of the TASA study are
linked to whether the study intervention can reduce or
smooth health service utilization. Previously identified
health service impacts of synchronized social assistance in-
clude ED, EDMH or SUH admissions [7, 11–13, 19, 57];
discharges against medical advice directly prior to cheque
issue [7, 9, 12]; health service access barriers linked to ele-
vated demand [6]; and interruptions to ongoing medical
care [9, 22]. In support of these assessments the study
instrument collects past six months (baseline) and past
2 weeks (baseline and follow-up) information on which
health services were accessed, whether participants
attempted but were unable to access a service, the tim-
ing and reason for encountering service access barriers
and whether participants missed medical appointments
around cheque issue. We additionally collect informa-
tion on whether, if hospitalized, participants left hos-
pital against medical advice, as well as the reasons for
and timing of their departure.
Social service utilization
Social assistance recipients’ use of social services, such
as meal programs, outreach services or drop-in centres,
may similarly undergo cyclical changes or face barriers
to accessing services at times when these are oversub-
scribed. Similar to health care utilization indicators, the
study instrument includes questions asking participants
about social service access, barriers to accessing services
and the timing of service access barriers in relation to
cheque issue in the past six months (baseline) and past
2 weeks (baseline and follow-up).
Income and material security
Consideration of income generation is critical given that
many social assistance recipients supplement their income
with illegal or prohibited income generation (e.g., sex
work, drug dealing) [14, 15], and that such activities are
associated with health harms [14, 15, 56]. Therefore, chan-
ging assistance patterns may change patterns of other in-
come generation. To assess the impact of the intervention
on financial well being, we measure income generation ac-
tivity, income amounts and material security in the past
six months (baseline), and past 2 weeks (baseline and
follow-up). Data referring to the past six months is col-
lected using an instrument verified for use in the current
study context [15, 58]. Data referring to the 2 weeks prior
to interview is collected by expanding the use of the
Timeline Followback instrument to track daily income
generation information, including sources and estimated
daily earnings. Material security in the past six months
(baseline) and past 2 weeks (baseline and follow-up) is
assessed using a validated scale [59] that has been adapted
to the current study context. Further measures include
involvement in acquisitive criminal activity, such as theft,
as well as amounts of drug debt accumulation and to
whom drug debt is owed.
Quality of life
To support health economic evaluation, the Canadian
Euroqol Group EQ-5D [60, 61] will be administered at
baseline and all follow-up visits. The EQ-5D can be
administered quickly and measures health related quality
of life and includes participant self-reports of mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression, as well as a health thermometer ranking of a
participant’s overall state of health, and has been
validated for use among PWUD [62].
Study-related measures
To assess considerations related to the study and study
intervention that may affect study outcomes, at baseline
we collect information on individual’s motivations to
participate in the study (e.g., financial compensation,
desire to reduce drug use around cheque issue) and their
treatment arm preference. At baseline and the final
follow-up visit, participants complete the client satisfac-
tion questionnaire (CSQ), a validated instrument [63]
that assesses satisfaction with services and is used here
to measure participant perceptions about social assistance
receipt, including the degree to which social assistance and
related Ministry of Social Development and Social
Innovation supports meet needs, help with problems, and
are satisfactory. Additionally, for participants that withdraw
from the intervention prior to completing their 26-week
intervention period, questions are asked about their
reasons for and circumstances surrounding withdrawal. At
the final study follow-up we assess participant experiences,
including participant opinions about the benefits and
drawbacks of their intervention and best options for
cheque issue timing and frequency.
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Participant safety
The design of the current trial does not involve any
change in the amount of social assistance provided to
participants, and we therefore do not anticipate any
negative changes to their financial well-being. However,
desynchronizing social assistance may disrupt money
management strategies, potentially interfering with the
payment of expenses. Importantly, most participants in
the TASA study have the rent portion of their social
assistance paid directly to their landlords. Participants
who have rent or other expenses can make arrangements
on a case-by-case basis with Pigeon Park Savings to
ensure the availability of funds at the appropriate time.
Additionally, for staggered and split arm participants,
receiving multiple payments per month may result in
more frequent periods of intensified drug use, albeit
these periods will likely be shorter or less intense given
that less money will be disbursed at any one time. For
intervention participants, there may also be challenges
transitioning onto or off of a new social assistance
payment schedule at the start or end of the study period.
To mitigate this concern, study staff members can
provide referrals to financial management support
services as appropriate. We do not anticipate the study
will expose participants to unusual risks. Nevertheless,
we monitor participant safety as a part of each bi-weekly
participant assessment, including considerations of food
and housing insecurity, exposure to violence, access to
critical health and social services and other emerging
issues. We follow standard reporting procedures for ad-
verse events and serious adverse events [64], including
oversight from an external, independent Data Safety and
Monitoring Committee (DSMC). Participants are able to
withdraw from the intervention, the study, or both at
any point, and may be withdrawn from either by investi-
gators in the event of concerns over safety.
Sample size
We base sample size calculations for the TASA study on
an a priori minimum clinically important difference
(MCID) in the rate of individuals reporting intensified
drug use on government cheque issue days between con-
trol and non-control participants. For the purposes of
sample size calculations, comparisons were drawn be-
tween control and staggered arm participants. We an-
ticipate this intervention will have a lesser impact on the
primary outcome of interest than the staggered and split
arm and should therefore provide basis for sample size
calculations. Given a lack of prior comparable experi-
mental research, the MCID was set conservatively to a
20 % difference between control and staggered interven-
tion arm participants. This MCID was based on results
from previous observational studies that report increases
in the rates of drug related harm between 24.9 and
81.2 % in the days surrounding government cheque issue
[5, 7, 12, 13, 17–20, 57]. We combined this MCID with
an estimate of 85 % of individuals in the control group
reporting intensified substance use on community
cheque issue day (Pc). This was set lower than 100 % to
account for potential reporting biases at study screening,
where all participants must indicate elevated use in
order to be eligible, as well as any study participation
effect on the outcome of interest among control arm
participants.
Sample size calculations used methods to detect differ-
ences between proportions in a repeated measures de-
sign and were calculated using Power and Sample Size
(PASS v.12) software. Sixty-five participants per arm
completing all follow-ups would allow the detection of a
20 % difference in the rates of intensified drug use
between control and staggered intervention arm partici-
pants with 80 % power at a 5 % significance level. These
calculations assumed that control and intervention arm
rates of intensified drug use follow a Bernoulli distribution,
the number of government cheque issue days falling
within the observation period is 6 and, as in previous stud-
ies involving PWUD [65], the autocorrelation between
measures of the same individual over time (ρ) is 0.6. Based
on previous studies among PWUD, and noting the import-
ance of accounting for missed follow-up visits and loss to
follow-up [66], we additionally account for observation-
level non-response of 33 % and a potential rate of loss to
follow-up of 25 %, reaching a final sample size of 91
individuals per arm or 273 in total across all three arms.
The possibility of type II, false negative findings, could re-
sult from insufficient power, or, in the event of interven-
tion withdrawal, the dilution of the effect of the
intervention in ITT analyses from participants who have
resumed regular synchronized payments but are analyzed
as part of the intervention arm. These risks will be partially
mitigated by the inclusion of sensitivity analyses, as out-
lined in the Data Analysis section below.
Data linkages
To verify participant self-report wherever possible, and
supplement data for the assessment of cheque issue-
related costs incurred by institutions that provide social,
health, financial and security (i.e., policing) services to
PWUD and their communities, we will obtain third party
service provision and administrative records from external
databases on all participants. Participant records will be
requested from hospitals, health service providers, the
provincial prescription medication database, Provincial
Ministry of Social Development and Social Innovation,
study partner credit union, and police and criminal justice
databases. Records will be requested for a 30-month
period beginning 1 year before the beginning of active
study participation through to 1 year after following the
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completion of active study participation in order to assess
the impact of study involvement on access to medical and
social services over time. Data linkages will be established
through participant names, birth dates and participants’
personal health number, a unique and persistent identifier
issued for medical billing and tracking purposes to all resi-




At the conclusion of the trial, the primary and secondary
endpoints will be assessed via intention-to-treat analyses
[67], including all patients randomized regardless of com-
pliance with the intervention protocol. Sub-analyses will
include a modified intention-to-treat analysis that will use
all participants with at least one follow-up [67, 68]. First,
we will compile descriptive characteristics of the sample,
assessing for systematic differences in key characteristics
across study arms using the Chi-Square test for binary vari-
ables and the Mann-Whitney U test for continuous vari-
ables. The primary outcome of interest will be derived
from TLFB information as a repeated binary variable (in-
tensified drug use on the 3 days beginning with govern-
ment cheque issue day vs. not) and will be quantified as
the proportion of individuals TASA participants reporting
increased drug use during this period at each government
cheque issue. This outcome, and other secondary out-
comes similarly quantified will be examined using pooled
generalized linear mixed effects models, with binomial dis-
tribution and logit link specified to produce unadjusted
and adjusted odds ratios and 95 % confidence intervals.
Other secondary outcomes of interest, quantified as counts
of the number of occurrences over the course of the obser-
vation period (e.g., hospital ED admissions), will be exam-
ined using generalized linear mixed-effects model, with a
Poisson distribution and a log link specified for count data
with corrections for overdispersion, including a Vuong test
for overdispersion and, where indicated, the use of a nega-
tive binomial model [69]. All analyses will include binary
indicators of study arm allocation to assess for systematic
differences in primary and secondary outcomes of interest
across study arms. Multivariate analyses will be adjusted
for: (1) binary indicators of the type of income assistance
the participant receives; (2) an indicator variable for
whether the individual changed their financial service pro-
vider to Pigeon Park Savings (PPS) at the start of the study
to control for the effect of becoming a PPS client; (3)
socio-demographic characteristics, including gender, ethni-
city and age; indicators of addiction treatment enrollment
and DTES residency, and (4) a categorical variable for the
number of days between government cheque issue and
their study visit to account for differences in recall reliabil-
ity. As is common in RCT analyses [70, 71], missing
assessments of intensified drug use will be treated as
positive and tested for sensitivity to this assumption
[72, 73]. Additional sensitivity analyses will include: (1)
a modified intention-to-treat analysis using all partici-
pants with at least one follow-up assessment [74]; and
(2) per-protocol analyses of participants who maintain
enrollment in the intervention [75, 76].
Qualitative analysis
Following verbatim transcription of interview audio-
recordings, we will inductively generate a coding frame-
work capturing a priori key analytic constructs derived
from the topic guide as well as emergent themes derived
from interview transcripts, continuously refining and
consolidating code categories. Qualitative data will be
contextualized through linkages to TASA questionnaire
data in terms of individual participation trajectories,
adverse events and serious adverse events. Data from
second and third interviews will test the boundaries of
existing categories where overlap in substantive content
exists, identify new conceptual categories and examine
negative or inconsistent evidence. Particular focus will
be on experiences of synchronized and unsynchro-
nized cheque issue days among intervention partici-
pants to explore the role of individual and social cues
for drug use. We will also compare experiences of
drug use, drug-related harm and changes to financial
management strategies between individuals allocated
to different intervention arms. Longitudinal data col-
lection will provide opportunities for participants to
provide feedback on emerging analyses and reflect on
earlier study experiences.
Economic evaluation
The economic evaluation of the TASA study will involve
a cost-utility analysis to determine the cost-effectiveness
of the study interventions. We will adopt a societal per-
spective that includes the direct (healthcare utilization:
medication, inpatient and outpatient care) and indirect
(criminal activity and lost productivity) consequences of
different social assistance disbursement arrangements.
Incremental cost-effectiveness ratios (ICERs) will be calcu-
lated for the 26-week timeframe of individual using trial-
based analysis, contrasted with results from a model-based
analysis projecting up to a lifetime horizon by adapting a
previously-developed model [77]. Statistical analyses will
include: (1) Cost estimation; (2) Health-related quality of
life (HRQoL) assessment and valuation; (3) Incremental
cost-effectiveness analysis; and (4) Analysis of uncertainty.
The relevant costing data includes intervention costs,
health resource utilization and criminality, all collected at
follow-up via standardized or verified instruments, with
previously-used unit cost sources [77]. The number of
quality-adjusted life-years (QALYs) [78] accumulated
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during the study period for each individual will be esti-
mated using the Euroqol EQ-5D [62]. We will augment
standardized measurement by quantifying QALY loss due
to overdose via direct assessment at baseline.
ICERs will be calculated in the typical formulation,
for both the trial- and model-based analyses [79].
Additionally, we propose a net-benefit regression ap-
proach for the trial-based analysis, using established
econometric techniques [80], allowing for subgroup
assessment of cost-effectiveness. Uncertainty around
ICERs will be quantified using non-parametric boot-
strapping and Monte Carlo simulation for trial- and
model-based analyses, respectively [81]. This information
can then be used to inform whether it is worthwhile to
collect further information to clarify the decision rule, in
the event that there is no clear choice among control or
intervention strategies, or if there is a high level of uncer-
tainty in the decision [82]. The analysis will conform to
guidelines on cost-effectiveness analyses conducted along-
side clinical trials [77, 83].
Study oversight
TASA is monitored by an independent DSMC comprised
of a biostatistician, epidemiologist, addictions physician
and community service provider with detailed knowledge
of the interests of the target study population. The DSMC
can recommend study stoppage for reasons of efficacy, re-
cruitment or participant safety, and meets semi-annually.
Data concerning adverse events and serious adverse
events are provided in real time, and study investigators
submit quarterly reports on participant recruitment and
retention. Interim analyses whose results are to be re-
ported to the DSMC are scheduled following the recruit-
ment and study completion of the first third and second
third of study participants. Any protocol modifications
will be subject to further approval form the ethical review
and reported to all study investigators, trial registries,
journals and, where relevant, trial participants.
Data management and quality assurance
Each participant is assigned a unique numeric study iden-
tifier code at the beginning of their enrollment in the
TASA trial to enable the de-identification of data. Confi-
dential electronic questionnaire data and completed hard
copy forms will be entered into a password-protected
Oracle database. Qualitative data stored in electronic files,
including interview recordings, interview transcripts as
well as field-notes will be password protected. Hard copies
of field notes, consent forms, and interview transcripts will
be stored in locked filing cabinets in the secure field
research office in space restricted exclusively to study staff
and maintained by study investigators. All participant data
and digital research documents are stored in encrypted
files on secure servers at the British Columbia Centre for
Excellence in HIV/AIDS, and only the Principal Investiga-
tor and key study personnel have access to any data
containing personal identifiers to facilitate participant
safety and monitoring and data linkages. Study personnel
perform random checks to verify the accuracy of data in-
put into the clinical trial database, and triangulation will
be undertaken to identify and rectify any deficiencies to
ensure data integrity. Trained personnel conduct the
TASA study according to standard operating procedures
and the principles of Good Clinical Practice.
Discussion
The unintended health, social and economic harms result-
ing from synchronized monthly social assistance are well
documented [5–7, 9–13, 16–24]. However, the lack of con-
trolled experimental studies examining alternate disburse-
ment strategies impedes the development of evidence-
informed policies that could preserve the important finan-
cial security and other benefits of social assistance while de-
creasing their role in the production of drug-related harm.
The TASA study is the first RCT that begins to address the
significant gap in our understanding of potential alterna-
tives to a considerable driver of avoidable morbidity and
mortality, elevated costs to communities and challenges to
service provision. By providing robust research exploring
interventions to address both the individual and social ef-
fects of current disbursement policies, the study is being
conducted with a view to identify strategies that are better
able to promote public health and safety. This study there-
fore has considerable implications for policy makers given
the longstanding and widespread recognition of
disbursement-related harm in multiple jurisdictions [7, 8,
21, 84].
The study also represents a notable innovation in
experimental and trial-based research in addictions by
focusing on a structural intervention that alters the
characteristics of an upstream determinant of health-
individual income-to mitigate the effects of problematic
drug use and related harms. RCTs among PWUD have
overwhelmingly assessed behavioural drug use interven-
tions, and have, as a result, produced mixed evidence for
interventions that may be difficult to scale up or that
produce only short-term benefits [85–87]. In contrast,
the TASA study examines an intervention with signifi-
cant policy relevance and a high degree of scalability,
with the possibility for long-term, low-cost or cost-
averting implementation. Additionally, the measurement
of daily drug use patterns throughout the 26-week dur-
ation of each participant’s active study participation pro-
duces a robust platform for analyses. The supplementation
of study data with information from third-party databases
will additionally allow for data triangulation and robust ser-
vice utilization and cost-benefit analyses to determine
whether either of the tested interventions holds the
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potential to produce system-wide efficiencies and reduce
service provision challenges around government cheque
issue. The study additionally benefits from widespread
community acknowledgement of the issues and challenges
of synchronized social assistance and strong community
partnerships in support of the study and the assessment of
alternative approaches.
The TASA study uniquely examines an upstream
determinant of health and the unintended but negative
consequences of public policy on the outcomes of vul-
nerable and marginalized populations. In testing changes
to the structural conditions of social assistance receipt
for PWUD through a community-based RCT, the TASA
study advances the field of experimental addictions re-
search. The inclusion of a paired nested qualitative parallel
process evaluation and economic cost-effective analyses
provide a robust platform for understanding the impacts,
mechanisms of action and cost implications of alternative
approaches to synchronized monthly social assistance
disbursement. There is significant potential, therefore, for
TASA study findings to directly support evidence-informed
changes to social assistance disbursement policy in British
Columbia, Canada and internationally.
Abbreviations
AMA, against medical advice, CAD, Canadian dollars, CRISM, Canadian Research
Initiative in Substance Misuse, CSQ, client satisfaction questionnaire, DSMC, Data
Safety and Monitoring Committee, DTES, Downtown Eastside, ED, emergency
department, EDMH, emergency department metnal health, HRQoL, health-
related quality of life, ICER, Incremental cost-effectiveness ratios, PPS, Pigeon
Park Savings, PWUD, people who use illicit drugs, QALY, quality adjusted life
yearsRCT, Randomized controlled trial, SIF, supervised injection facility, SUH,
substance use hospitalization TLFB, Timeline follow back instrument
Acknowledgments
Pigeon Park Savings, a PHS Community Services Society operated branch of
Vancouver City Savings and Credit Union, administers the intervention. PPS is
not involved in participant recruitment, randomization or the collection of
baseline or follow-up data.
We thank the following for their contribution to the study: Michelle Davey
(Vancouver Police Department), Kenneth Tupper (BC Ministry of Health),
Vancouver Area Network of Drug Users (VANDU), Western Aboriginal Harm
Reduction Society (WAHRS), Joel Singer, Emanuel Krebs, Jennifer Matthews,
Tricia Collingham, Kristie Starr, and Ana Prado.
LR and MJM are supported by Canadian Institutes for Health Research New
Investigator Awards and Michael Smith Foundation for Health Research
(MSFHR) Scholar Awards. MJM is additionally supported in part by the United
States National Institutes of Health (R01-DA0251525). BM is supported by the
NIH (DP2-DA040236) and by a Henry Merrit Wriston Fellowship from Brown
University. WS is supported by a MSFHR Scholar Award. EW is supported by
a Tier 1 Canada Research Chair in Inner City Medicine. JM is supported by
the British Columbia Ministry of Health and through an Avant-Garde Award
(No. 1DP1DA026182) from the National Institute of Drug Abuse (NIDA), at
the US National Institutes of Health (NIH).
Funding
The TASA study is supported by the Canadian Institutes of Health Research
(MOP 136827, MOP 137068), the Peter Wall Institute, the Michael Smith
Foundation for Health Research and a PHCRI and VCHRI joint Innovation
and Translational Award funded by the Providence Health Care Research
Institute. Funding bodies had no role in the design of the study, the writing
of the manuscript or the decision to submit the manuscript for publication.
Availability of data and material
Upon completion of data collection, study data will not be publicly available
due to the sensitivity of data and requirements of third party database
administration.
Authors’ contributions
LR, MJM and TK conceptualized the study. LR developed the protocol, is
the Principal Investigator on the grants that support the project, oversees all
aspects of the study, and wrote the first draft of the manuscript. AL led the
development of operational procedures. All other investigators contributed
to the study design and have provided key substantive and editorial input
into the protocol and manuscript. All authors have read and approved the
final manuscript.
Competing interests
MJSM’s institution has received an unstructured gift from NG Biomed, Ltd.
to support his research. JM’s TasP research, paid to institution, has received
support from the BC-Ministry of Health, US NIH (NIDA R01DA036307),
UNAIDS, and MAC AIDS Fund. Institutional grants have been provided to
JM by Abbvie, BMS, Gilead Sciences, J&J, Merck and ViiV Healthcare.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study has received ethics approval from the University of British
Columbia/Providence Health Care Research Ethics Board (H14-02401). All
participants are required to provide written informed consent following prior
to their enrollment in the study. Separate release of information consent
forms are completed by participants to grant permission to obtain their
personal records from external databases, including hospitals, health service
providers, the provincial prescription medication database, Provincial Ministry
of Social Development and Social Innovation, the study partner credit union,
police and criminal justice databases and emergency health services.
Author details
1British Columbia Centre for Excellence in HIV/AIDS, St. Paul’s Hospital,
608-1081 Burrard Street, Vancouver V6Z 1Y6, BC, Canada. 2Department of
Sociology, University of British Columbia, 6303 NW Marine Drive, Vancouver
V6T 1Z1, BC, Canada. 3Faculty of Medicine, Division of AIDS, University of
British Columbia, St. Paul’s Hospital, 608-1081 Burrard Street, Vancouver V6Z
1Y6, BC, Canada. 4PHS Community Services Society, 20 Hastings Street W,
Vancouver V6B 1G6, BC, Canada. 5Faculty of Health Sciences, Simon Fraser
University, 8888 University Drive, Burnaby V5A1S6, BC, Canada. 6Department
of Epidemiology, School of Public Health, Brown University, 121 South Main
Street, Providence 02912, RI, USA. 7Department of Emergency Medicine,
Faculty of Medicine, University of British Columbia, 910 West 10th Ave,
Vancouver V5Z 1 M9, BC, Canada. 8Vancouver Coastal Health, 601 West
Broadway, Vancouver V5Z 4C2, BC, Canada. 9School of Population and Public
Health, University of British Columbia, 2206 East Mall, Vancouver V6T 1Z3, BC,
Canada.
Received: 7 July 2016 Accepted: 14 July 2016
References
1. Boychuk GW. Patchworks of Purpose: The Development of Provincial Social
Assistance Regimes in Canada. Montreal: McGill-Queens University Press;
1999.
2. Nelson K. Mechanisms of poverty alleviation: anti-poverty effects of
non-means-tested and means-tested benefits in five welfare states.
J Eur Soc Policy. 2004;14:371–90.
3. Stephens M. 3rd of tha month”: Do social security recipients smooth
consumption between checks? Am Econ Rev. 2003;93:406–22.
4. Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL.
Real-time electronic diary reports of cue exposure and mood in the hours
before cocaine and heroin craving and use. Arch Gen Psychiatry.
2009;66:88–94.
5. Zlotorzynska M, Milloy M, Richardson L, Montaner J, Wood E, Kerr T.
Timing of social assistance payment and overdose patterns at a Canadian
supervised injection facility. Int J Drug Pol. 2014;25:736–9.
Richardson et al. BMC Public Health  (2016) 16:668 Page 14 of 16
6. Small W, Shoveller J, Moore D, Tyndall M, Wood E, Kerr T. Injection drug
users’ access to a supervised injection facility in Vancouver, Canada: the
influence of operating policies and local drug culture. Qual Health Res.
2011;21:743–56.
7. Verheul G, Singer SM, Christenson JM. Mortality and morbidity associated
with the distribution of monthly welfare payments. Acad Emerg Med.
1997;4:118–23.
8. Rosen MI. The ‘check effect’ reconsidered. Addiction. 2011;106:1071–7.
9. Chan AC, Palepu A, Guh DP, Sun H, Schechter MT, O’Shaughnessy MV, Anis
AH. HIV-positive injection drug users who leave the hospital against medical
advice: the mitigating role of methadone and social support. J Acquir
Immune Defic Syndr. 2004;35:56–9.
10. Shaner A, Eckman TA, Roberts LJ, Wilkins JN, Tucker DE, Tsuang JW, Mintz J.
Disability income, cocaine use, and repeated hospitalization among
schizophrenic cocaine abusers—a government-sponsored revolving door?
N Engl J Med. 1995;333:777–83.
11. Brunette DD, Kominsky J, Ruiz E. Correlation of emergency health care use,
911 volume, and jail activity with welfare check distribution. Ann Emerg
Med. 1991;20:739–42.
12. Riddell C, Riddell R. Welfare checks, drug consumption, and health evidence
from Vancouver injection drug users. J Hum Resour. 2006;41:138–61.
13. Catalano R, McConnell W. Psychiatric emergencies: the check effect
revisited. J Health Soc Behav. 1999;40:79.
14. Richardson L, Milloy M, Kerr T, Guillemi S, Hogg R, Harrigan R,
Montaner J, Wood E. Socio-economic marginalization and virologic
suppression among antiretroviral therapy-exposed individuals who use
illicit drugs. AIDS. 2015;29:2487–95.
15. Debeck K, Shannon K, Wood E, Li K, Montaner J, Kerr T. Income generating
activities of people who inject drugs. Drug Alcohol Depend. 2007;91:50–6.
16. Dobkin C, Puller SL. The effects of government transfers on monthly cycles
in drug abuse, hospitalization and mortality. J Pub Econ. 2007;91:2137–57.
17. Li X, Sun H, Marsh DC, Anis AH. Impact of welfare cheque issue days on a
service for those intoxicated in public. Harm Reduct J. 2007;4:1–4.
18. Catalano R, McConnell W, Forster P, Mcfareland B, Shumway M, Thornton D.
Does the Disbursement of Income Increase Psychiatric Emergencies
Involving Drugs and Alcohol? Health Serv Res. 2000;35:813–23.
19. Halpern SD, Mechem CC. Declining rate of substance abuse throughout
the month. Am J Med. 2001;110:347–51.
20. Phillips DP, Christenfeld N, Ryan NM. An increase in the number of deaths
in the united states in the first week of the month—an association with
substance abuse and other causes of death. N Engl J Med. 1999;341:93–8.
21. Otterstatter MC, Amlani A, Guan H, Richardson L, Buxton J. Illicit drug
overdose deaths resulting from income assistance payments: Analysis of the
‘check effect’ using daily mortality data. Int J Drug Pol. 2016;33: 83–7. In
Press.
22. Anis AH, Sun H, Guh DP, Palepu A, Schechter MT, O’Shaughnessy MV.
Leaving hospital against medical advice among HIV-positive patients. CMAJ.
2002;167:633–7.
23. Svikis DS, Pickens RW, Schweitzer W, Johnson E, Haug N. Weekly patterns of
drug treatment attendance. Am J Public Health. 1999;89:752–5.
24. Pickett T, Stenstrom R, Abu-Laban R. Association between mental health
apprehensions by police and monthly income assistance (welfare)
payments. Can J Psychiatry. 2015;60:146–50.
25. Parsons CA, Van Wesep ED. The timing of pay. J Financ Econ.
k2013;109:373–97.
26. Anakwenze U, Zuberi D. Mental health and poverty in the inner city. Health
Soc Work. 2013;38:147–57.
27. Liu S, Blomley N. Making news and making space: framing Vancouver’s
downtown eastside. Can Geogr. 2013;57:119–32.
28. Krebs E, Wang L, Olding M, Hayashi K, Milloy M, DeBeck K, Wood E, Kerr
T, Nosyk B. Increased drug use and the timing of social assistance receipt
among people who use illicit drugs. Under Review.
29. Blankenship KM, Friedman SR, Dworkin S, Mantell JE. Structural
interventions: concepts, challenges and opportunities for research.
J Urban Health. 2006;83:59–72.
30. Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline
followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav.
2014;28:154–62.
31. Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for
self-reported use of cannabis and other illicit substances—systematic review
and meta-analysis. Addict Behav. 2012;37:225–33.
32. Oakley A, Strange V, Bonell C, Allen E, Stephenson J, RIPPLE Study Team.
Process evaluation in randomised controlled trials of complex interventions.
BMJ. 2006;332:413–6.
33. Nutt DJ, King LA, Phillips LD, Independent Scientific Committee On
Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet.
2010;376:1558–65.
34. Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML,
Montaner JSG, Schechter MT, O'Shaughnessy MV. Needle exchange is
not enough: lessons from the Vancouver injecting drug use study.
AIDS. 1997;11:F59–65.
35. Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, Montaner
J, Wood E. Homelessness as a structural barrier to effective antiretroviral
therapy among HIV-seropositive illicit drug users in a Canadian setting.
AIDS Patient Care STDS. 2012;26:60–7.
36. Urban Health Research Initiative. Drug Situation in Vancouver, 2nd Ed.
Urban Health Research Initiative, British Columbia Centre for Excellence in
HIV/AIDS, June 2013.
37. Efird J. Blocked randomization with randomly selected block sizes. Int
J Environ Res Public Health. 2011;8:15–20.
38. Buu A, Li R, Walton MA, Yang H, Zimmerman MA, Cunningham RM.
Changes in Substance Use-Related Health Risk Behaviors on the Timeline
Follow-Back Interview as a Function of Length of Recall Period. Subst Use
Misuse 2014
39. Patton MQ. Qualitative evaluation and research methods. Newbery Park:
Sage; 1990.
40. Teddlie C, Yu F. Mixed methods sampling: a typology with examples.
J Mixed Methods Res. 2007;1:77–100.
41. Kerr T, Kimber J, Rhodes T. Drug use settings: an emerging focus for
research and intervention. Int J Drug Policy. 2007;18:1–4.
42. Davidson P, Page K. Research participation as work: comparing the
perspectives of researchers and economically marginalized populations.
Am J Public Health. 2012;102:1254–9.
43. Shannon K, Ishida T, Lai C, Tyndall MW. The impact of unregulated single
room occupancy hotels on the health status of illicit drug users in
Vancouver. Int J Drug Pol. 2006;17:107–14.
44. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and
illicit drug users: a meta-analysis of randomized controlled trials. J Stud
Alcohol Drugs. 2009;70:516–27.
45. Kilmer B, Everingham SS, Caulkins JP, Midgette G, Pacula RL, Reuter PH,
Burns RM, Han B, Lundberg R, Corporation R. What Americas users spend
on illegal drugs, 2000–2010. Washington: Office of National Drug Control
Policy; 2014.
46. Singleton N, Murray R, Tinsley L. Measuring different aspects of problem
drug use: methodological developments. 2006. Home Office London.
https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/116642/hoor1606.pdf. Accessed 14 February 2016.
47. Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors
that shape assisted injecting practices among injection drug users in
Vancouver. Can: qual study Harm Reduct J. 2010;7:20.
48. Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, Wood E. Syringe
sharing and HIV incidence among injection drug users and increased
access to sterile syringes. Am J Public Health. 2010;100:1449–53.
49. Miller CL, Kerr T, Frankish JC, Spittal PM, Li K, Schechter MT, Wood E. Binge
drug use independently predicts HIV seroconversion among injection
drug users: implications for public health strategies. Subst Use Misuse.
2006;41:199–210.
50. Ivsins A, Roth E, Benoit C, Fischer B. Crack pipe sharing in context: How
sociostructural factors shape risk practices among noninjection drug users.
Contemp Drug Problems. 2013;40:481–503.
51. Small W, Rhodes T, Wood E, Kerr T. Public injection settings in
Vancouver: physical environment, social context and risk. Int J Drug
Policy. 2007;18:27–36.
52. Kerr T, Small W, Johnston C, Li K, Montaner JS, Wood E. Characteristics of
injection drug users who participate in drug dealing: implications for drug
policy. J Psychoactive Drugs. 2008;40:147–52.
53. Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised
injection services: what has been demonstrated? a systematic literature
review. Drug Alcohol Depend. 2014;145:48–68.
54. Werb D, Rowell G, Guyatt G, Kerr T, Montaner J, Wood E. Effect of
drug law enforcement on drug market violence: a systematic review.
Int J Drug Policy. 2011;22:87–94.
Richardson et al. BMC Public Health  (2016) 16:668 Page 15 of 16
55. Debeck K, Wood E, Zhang R, Tyndall M, Montaner J, Kerr T. Police and
public health partnerships: evidence from the evaluation of Vancouver’s
supervised injection facility. Subst Abuse Treat Prev Policy. 2008;3:1–5.
56. Richardson L, Long C, Nguyen P, Debeck K, Milloy MJ, Wood E, Kerr T.
Socio-economic marginalization in the structural production of vulnerability
to violence among people who use illicit drugs. J Epidemiol Community
Health. 2015;69:686–92.
57. Maynard C, Cox GB. Association between week of the month and
hospitalization for substance abuse. Psychiatr Serv. 2000;51:31.
58. Long C, Debeck K, Feng C, Montaner J, Wood E, Kerr T. Income level and
drug related harm among people who use injection drugs in a Canadian
setting. Int J Drug Pol. 2014;25:458–64.
59. Ompad DC, Nandi V, Cerdá M, Crawford N, Galea S, Vlahov D. Beyond
income: material resources among drug users in economically-
disadvantaged New York city neighborhoods. Drug Alcohol Depend.
2012;120:127–34.
60. Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D
health states: preliminary value set and considerations for future valuation
studies. PLoS One. 2012;7, e31115.
61. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia
X. Development and preliminary testing of the new five-level version of
EQ-5D (EQ-5D-5 L). Qual Life Res. 2011;20:1727–36.
62. Nosyk B, Sun H, Guh DP, Oviedo-Joekes E, Marsh DC, Brissette S, Schechter
MT, Anis AH. The quality of eight health status measures were compared
for chronic opioid dependence. J Clin Epidemiol. 2010;63:1132–44.
63. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric
properties and correlations with service utilization and psychotherapy
outcome. Eval Program Plann. 1982;5:233–7.
64. Leape LL. Reporting of adverse events. N Engl J Med. 2002;347:1633–8.
65. Avants SK, Margolin A, Holford TR, Kosten TR. A randomized controlled
trial of auricular acupuncture for cocaine dependence. Arch Intern Med.
2000;160:2305–12.
66. Hansten ML, Downey L, Rosengren DB, Donovan DM. Relationship between
follow-up rates and treatment outcomes in substance abuse research: more
is better but when is “enough” enough? Addiction. 2000;95:1403–16.
67. Newell DJ. Intention-to-treat analysis: implications for quantitative and
qualitative research. Int J Epidemiol. 1992;21:837–41.
68. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs.
Biometrics. 1996;52:1324–33.
69. Yang Z, Hardin JW, Addy CL, Vuong QH. Testing approaches for
overdispersion in Poisson regression versus the generalized Poisson model.
Biom J. 2007;49:565–84.
70. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical
trial of a new behavioral treatment for drug abuse in people with severe
and persistent mental illness. Arch Gen Psychiatry. 2006;63:426–32.
71. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis
C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of
opioid dependence: a randomized, placebo-controlled trial. Arch Gen
Psychiatry. 2006;63:210–8.
72. Fielding S, Fayers P, Ramsay CR. Analysing randomised controlled trials
with missing data: choice of approach affects conclusions. Contemp Clin
Trials. 2012;33:461–9.
73. Brooner RK, Kidorf MS, King VL, Stoller KB, Neufeld KJ, Kolodner K.
Comparing adaptive stepped care and monetary-based voucher
interventions for opioid dependence. Drug Alcohol Depend.
2007;88 Suppl 2:S14–23.
74. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT,
Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A,
Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of
missing data in clinical trials. N Engl J Med. 2012;367:1355–60.
75. Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat
and per protocol analyses. J Clin Epidemiol. 2007;60:663–9.
76. Wright CC, Sim J. Intention-to-treat approach to data from randomized
controlled trials: a sensitivity analysis. J Clin Epidemiol. 2003;56:833–42.
77. Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC,
Meikleham E, Schechter MT, Anis AH. Cost-effectiveness of diacetylmorphine
versus methadone for chronic opioid dependence refractory to treatment.
CMAJ. 2012;184:E317–28.
78. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health.
2009;12:S5–9.
79. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-
effectiveness models: a suggested framework and example of application.
Pharmacoeconomics. 2000;17:461–77.
80. Hoch JS, Briggs AH, Willan AR. Something old, something new, something
borrowed, something blue: a framework for the marriage of health
econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30.
81. Briggs A. Handling uncertainty in economic evaluation and presenting the
results. In: Drummond M, McGuire A, editors. Economic evaluation in health
care: merging theory with practice. Oxford: Oxford University Press; 2001.
p. 172–214.
82. Nosyk B, Sharif B, Sun H, Cooper C, Anis AH. An economic evaluation and
value of information analysis of three influenza vaccination strategies for
patients with HIV/AIDS. PLoS One. 2011;6, e27059.
83. Brouwer WB, Koopmanschap M. How to calculate indirect costs in
economic evaluations. Pharmacoeconomics. 1998;13:563–9.
84. Swartz JA, Hsieh CM, Baumohl J. Disability payments, drug use and
representative payees: an analysis of the relationships. Addiction. 2003;98:
965–75.
85. Jepson RG, Harris FM, Platt S, Tannahill C. The effectiveness of interventions
to change six health behaviours: a review of reviews. BMC Public Health.
2010;10:538.
86. Klimas J, Field CA, Cullen W, O’Gorman CS, Glynn LG, Keenan E, Saunders J,
Bury G, Dunne C. Psychosocial interventions to reduce alcohol consumption
in concurrent problem alcohol and illicit drug users: Cochrane review. Syst
Rev. 2013;2:3.
87. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial
interventions for people with both severe mental illness and substance
misuse. Cochrane Database Syst Rev. 2013;10, CD001088.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Richardson et al. BMC Public Health  (2016) 16:668 Page 16 of 16
